DDInter672 DDInter1628
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Escitalopram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Escitalopram {u} (Compound) downregulates {v} (Gene) TSPAN4
TSPAN4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Escitalopram {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Escitalopram {u} (Compound) downregulates {v} (Gene) TSPAN4
TSPAN4 {u} (Gene) is regulated by {v} (Gene) JAK2
JAK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Escitalopram {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is regulated by {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Escitalopram {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Escitalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Ruxolitinib (Compound)
Escitalopram (Compound) downregulates TSPAN4 (Gene) and TSPAN4 (Gene) is downregulated by Ruxolitinib (Compound)
Escitalopram (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Escitalopram (Compound) downregulates TSPAN4 (Gene) and TSPAN4 (Gene) is regulated by JAK2 (Gene) and JAK2 (Gene) is bound by Ruxolitinib (Compound)
Escitalopram may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is regulated by IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Escitalopram may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)